Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22334236 | 0.80 | POLB (0.30) | POLB | |
| SCHEMBL7235362 | 0.79 | ALDH1A1 (0.33) | ALDH1A1ACHE | |
| SCHEMBL17358658 | 0.78 | POLB (0.31) | POLBLMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL12779376 | 0.76 | ACHE (0.32) | ACHE | |
| SCHEMBL3370983 | 0.76 | ACHE (0.32) | GLANPSR1LMNAMAPTKMT2A | |
| SCHEMBL7682479 | 0.76 | ACHE (0.32) | ALDH1A1ACHE | |
| SCHEMBL12844899 | 0.76 | ACHE (0.32) | ACHE | |
| SCHEMBL6948155 | 0.76 | ACHE (0.32) | ACHE | |
| SCHEMBL7237918 | 0.74 | PTPN1 (0.35) | LMNAL3MBTL1ALDH1A1ACHE | |
| SCHEMBL178866 | 0.73 | L3MBTL1 (0.32) | L3MBTL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368264-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368264-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | CPS1, SDHA, DHPS | GLA 1886/4885NPSR1 1445/4885POLB 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.